Technical feasibility and oncological legitimacy of enucleation of intraductal papillary mucinous neoplasm located at the pancreatic head or uncinate process

Yuji Soejima, Takeo Toshima, Takashi Motomura, Tomoyuki Yokota, Kouji Joko, Yumi Oshiro, Ikuo Takahashi, Takashi Nishizaki, Yoshihiko Maehara

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Surgical indications and strategies for branch duct (BD)-intraductal papillary mucinous neoplasm (IPMN) at the pancreatic head (PH) are controversial issues. We investigated the technical feasibility and oncological legitimacy of enucleation for IPMN of the PH. Patients and Methods: The clinicopathological parameters of 11 patients with IPMN who underwent conventional pancreaticoduodenectomy (PD, n=7) or enucleation (n=4) during the same period were evaluated. Results: The mean operative time (442 vs. 280 min, p<0.05) and blood loss (864 vs. 93 ml, p<0.05) were significantly better in the enucleation group. The final pathological diagnosis (low-/intermediate-/high-grade dysplasia) in the PD and enucleation groups was 4/2/1 and 3/1/0, respectively. The incidence of grade B pancreatic fistula and Clavien III complications was 14% vs. 0% and 43% vs. 25%, respectively. No recurrent pancreatitis or exocrine or endocrine dysfunction was noted in the enucleation group; however, de novo or exacerbated diabetes mellitus developed in three patients in the PD group. All patients were alive and no disease recurrence was noted at a mean follow-up of 1,059 days. Conclusion: Enucleation of BD-IPMN at the PH is a technically feasible and oncologically acceptable procedure which should be justified in patients with IPMNs with a low risk of malignancy.

Original languageEnglish
Pages (from-to)321-326
Number of pages6
JournalAnticancer research
Volume37
Issue number1
DOIs
Publication statusPublished - Jan 2017

Fingerprint

Illegitimacy
Pancreatic Neoplasms
Neoplasms
Pancreatic Fistula
Pancreaticoduodenectomy
Operative Time
Head and Neck Neoplasms
Pancreatitis
Diabetes Mellitus
Recurrence
Incidence

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Technical feasibility and oncological legitimacy of enucleation of intraductal papillary mucinous neoplasm located at the pancreatic head or uncinate process. / Soejima, Yuji; Toshima, Takeo; Motomura, Takashi; Yokota, Tomoyuki; Joko, Kouji; Oshiro, Yumi; Takahashi, Ikuo; Nishizaki, Takashi; Maehara, Yoshihiko.

In: Anticancer research, Vol. 37, No. 1, 01.2017, p. 321-326.

Research output: Contribution to journalArticle

Soejima, Y, Toshima, T, Motomura, T, Yokota, T, Joko, K, Oshiro, Y, Takahashi, I, Nishizaki, T & Maehara, Y 2017, 'Technical feasibility and oncological legitimacy of enucleation of intraductal papillary mucinous neoplasm located at the pancreatic head or uncinate process', Anticancer research, vol. 37, no. 1, pp. 321-326. https://doi.org/10.21873/anticanres.11324
Soejima, Yuji ; Toshima, Takeo ; Motomura, Takashi ; Yokota, Tomoyuki ; Joko, Kouji ; Oshiro, Yumi ; Takahashi, Ikuo ; Nishizaki, Takashi ; Maehara, Yoshihiko. / Technical feasibility and oncological legitimacy of enucleation of intraductal papillary mucinous neoplasm located at the pancreatic head or uncinate process. In: Anticancer research. 2017 ; Vol. 37, No. 1. pp. 321-326.
@article{76d511a92d354a1b99252d0a3862776b,
title = "Technical feasibility and oncological legitimacy of enucleation of intraductal papillary mucinous neoplasm located at the pancreatic head or uncinate process",
abstract = "Background: Surgical indications and strategies for branch duct (BD)-intraductal papillary mucinous neoplasm (IPMN) at the pancreatic head (PH) are controversial issues. We investigated the technical feasibility and oncological legitimacy of enucleation for IPMN of the PH. Patients and Methods: The clinicopathological parameters of 11 patients with IPMN who underwent conventional pancreaticoduodenectomy (PD, n=7) or enucleation (n=4) during the same period were evaluated. Results: The mean operative time (442 vs. 280 min, p<0.05) and blood loss (864 vs. 93 ml, p<0.05) were significantly better in the enucleation group. The final pathological diagnosis (low-/intermediate-/high-grade dysplasia) in the PD and enucleation groups was 4/2/1 and 3/1/0, respectively. The incidence of grade B pancreatic fistula and Clavien III complications was 14{\%} vs. 0{\%} and 43{\%} vs. 25{\%}, respectively. No recurrent pancreatitis or exocrine or endocrine dysfunction was noted in the enucleation group; however, de novo or exacerbated diabetes mellitus developed in three patients in the PD group. All patients were alive and no disease recurrence was noted at a mean follow-up of 1,059 days. Conclusion: Enucleation of BD-IPMN at the PH is a technically feasible and oncologically acceptable procedure which should be justified in patients with IPMNs with a low risk of malignancy.",
author = "Yuji Soejima and Takeo Toshima and Takashi Motomura and Tomoyuki Yokota and Kouji Joko and Yumi Oshiro and Ikuo Takahashi and Takashi Nishizaki and Yoshihiko Maehara",
year = "2017",
month = "1",
doi = "10.21873/anticanres.11324",
language = "English",
volume = "37",
pages = "321--326",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1",

}

TY - JOUR

T1 - Technical feasibility and oncological legitimacy of enucleation of intraductal papillary mucinous neoplasm located at the pancreatic head or uncinate process

AU - Soejima, Yuji

AU - Toshima, Takeo

AU - Motomura, Takashi

AU - Yokota, Tomoyuki

AU - Joko, Kouji

AU - Oshiro, Yumi

AU - Takahashi, Ikuo

AU - Nishizaki, Takashi

AU - Maehara, Yoshihiko

PY - 2017/1

Y1 - 2017/1

N2 - Background: Surgical indications and strategies for branch duct (BD)-intraductal papillary mucinous neoplasm (IPMN) at the pancreatic head (PH) are controversial issues. We investigated the technical feasibility and oncological legitimacy of enucleation for IPMN of the PH. Patients and Methods: The clinicopathological parameters of 11 patients with IPMN who underwent conventional pancreaticoduodenectomy (PD, n=7) or enucleation (n=4) during the same period were evaluated. Results: The mean operative time (442 vs. 280 min, p<0.05) and blood loss (864 vs. 93 ml, p<0.05) were significantly better in the enucleation group. The final pathological diagnosis (low-/intermediate-/high-grade dysplasia) in the PD and enucleation groups was 4/2/1 and 3/1/0, respectively. The incidence of grade B pancreatic fistula and Clavien III complications was 14% vs. 0% and 43% vs. 25%, respectively. No recurrent pancreatitis or exocrine or endocrine dysfunction was noted in the enucleation group; however, de novo or exacerbated diabetes mellitus developed in three patients in the PD group. All patients were alive and no disease recurrence was noted at a mean follow-up of 1,059 days. Conclusion: Enucleation of BD-IPMN at the PH is a technically feasible and oncologically acceptable procedure which should be justified in patients with IPMNs with a low risk of malignancy.

AB - Background: Surgical indications and strategies for branch duct (BD)-intraductal papillary mucinous neoplasm (IPMN) at the pancreatic head (PH) are controversial issues. We investigated the technical feasibility and oncological legitimacy of enucleation for IPMN of the PH. Patients and Methods: The clinicopathological parameters of 11 patients with IPMN who underwent conventional pancreaticoduodenectomy (PD, n=7) or enucleation (n=4) during the same period were evaluated. Results: The mean operative time (442 vs. 280 min, p<0.05) and blood loss (864 vs. 93 ml, p<0.05) were significantly better in the enucleation group. The final pathological diagnosis (low-/intermediate-/high-grade dysplasia) in the PD and enucleation groups was 4/2/1 and 3/1/0, respectively. The incidence of grade B pancreatic fistula and Clavien III complications was 14% vs. 0% and 43% vs. 25%, respectively. No recurrent pancreatitis or exocrine or endocrine dysfunction was noted in the enucleation group; however, de novo or exacerbated diabetes mellitus developed in three patients in the PD group. All patients were alive and no disease recurrence was noted at a mean follow-up of 1,059 days. Conclusion: Enucleation of BD-IPMN at the PH is a technically feasible and oncologically acceptable procedure which should be justified in patients with IPMNs with a low risk of malignancy.

UR - http://www.scopus.com/inward/record.url?scp=85007518276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007518276&partnerID=8YFLogxK

U2 - 10.21873/anticanres.11324

DO - 10.21873/anticanres.11324

M3 - Article

C2 - 28011509

AN - SCOPUS:85007518276

VL - 37

SP - 321

EP - 326

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1

ER -